G1-S transition defects occur in most breast cancers and predict outcome

Breast Cancer Research and Treatment

Volumn 56, Issue 2, 1999, Pages 105-112

  Nielsen, Niels Hilmer ^a   Lodén, Martin ^a   Cajander, Jenny ^a   Emdin, Stefan O ^a   Landberg, Göran ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Breast cancer; Cell cycle; Cyclins; P16; P27; Retinoblastoma protein; Survival

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN D; CYCLIN E; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P27; RETINOBLASTOMA PROTEIN;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032699133     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1006208419350     Document Type: Article

References (24)

1. Lees F.: Cyclin dependent kinase regulation. Current Opin Cell Biol 7: 773-780, 1995
2. Draetta GF: Mammalian GI cyclins. Current Opin Cell Biol 6: 842-846, 1994
3. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995
4. Strauss M, Lukas J, Bartek J: Unrestricted cell cycling and cancer. Nature Med 1: 1245-1246, 1995
5. Ohtsuba M, Theodoras AM, Schumacher J, Roberts JM, Pagano M: Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15: 2612-2624, 1995
6. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J: The p16-cyclin D CDK4 PRB pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 56: 5475-5483, 1996
7. Ichimura K, Schmidt EE, Goike HM. Collins VP: Human glioblastomas with no alterations of the CDKN2A (p16(INK4A), MTS1) and CDK4 genes have frequent mutations in the retinoblastoma gene. Oncogene 13: 1065-1072, 1996
8. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDK2N2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530, 1995
9. Loda M, Cukor B, Tam SW, Lavin P, Florentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3: 231-234, 1997
10. Landberg G, Roos G: The cell cycle in breast cancer. APMIS 105: 575-589, 1997
11. Lukas J, Aagard L, Straus M, Bartek J: Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res 55: 4818-4823, 1995
12. Pines J: Cyclins, CDKs and cancer. Semin Cancer Biol 6: 63-72, 1995
13. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996
14. Nielsen NH, Arneröv C, Emdin SO, Landberg G: Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 74: 874-880, 1996
15. Porter PL, Malone KE, Heagerty PJ, Alexancer GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3: 222-225, 1997
16. Nielsen NH, Emdin SO, Cajander J, Landberg G: Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene 14: 295-304, 1997
17. Dublin EA, Patel NK, Gillett CE, Smith P, Peters G, Barnes DM: Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int J Cancer 79: 71-75, 1998
18. Geradts J, Wilson PA: High frequency of aberrant p16(INK4A) expression in human breast cancer. Am J Pathol 149: 15-20, 1996
19. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3: 227-230, 1997
20. Tan P, Cady B, Wanner M, Worland P, Cukor B, MagiGalluzzi C, Lavin P, Draetta G, Pagano M, Loda M: The cell cycle inhibitor p27 is an independant prognostic marker in small (TIa,b) invasive breast carcinomas. Cancer Res 57: 1259-1263, 1997
21. Lovee H, Sewing A, Lucibello FC, Muller H, Möröy T: Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene 9: 323-326, 1994
22. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D: Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69: 92-99, 1996
23. Anderson JJ, Tiniakos DG, McIntosh GG, Autzen P, Henry JA, Thomas MD, Reed J, Home GM, Lennard TW, Angus B, Home CH: Retinoblastoma protein in human breast carcinoma: immunohistochemical study using a new monoclonal antibody effective on routinely processed tissues. J Pathol 180: 65-70, 1996
24. Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX, Xu HJ, Reuter VE, Benedict WF: Cooperative effects or p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 57: 1217-1221, 1997